Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2008-03-10 Investor Presentation
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Presention of Programs to International Partnering Meeting 2 pages ?Kb
Investor Presentation Classification · 85% confidence The document is a one-page announcement from Biotron Limited dated 11 March 2008, addressed to the Australian Stock Exchange. It reports on the company's presentation of its HIV and HCV clinical programs at an international partnering meeting. The content focuses on business development, clinical trial progress, and upcoming clinical trials. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The document is short (3172 characters) and serves as a corporate update or announcement rather than a detailed report or transcript. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Call Transcript. It is not a regulatory filing or certification. The best fitting category is Investor Presentation (IP) because it details the company's programs, clinical trial progress, and market potential aimed at investors and partners, even though it is a summary rather than a full presentation document. Given the short length and nature, confidence is moderate to high.
2008-03-10 English
Half Yearly Report and Accounts 18 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM FINANCIAL REPORT FOR THE HALF YEAR ENDED 31 DECEMBER 2007' and includes detailed financial statements such as the Interim Income Statement, Balance Sheet, Statement of Cash Flows, Directors' Report, and Auditor's Review Report. It covers the half-year period ending 31 December 2007, which is a period shorter than a full fiscal year. The document contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2008
2008-02-20 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash reconciliation, financing facilities, and compliance statements. It covers a quarterly period ending 31 December 2007. The content is substantive financial data for a period shorter than a full fiscal year, consistent with a quarterly or interim report. The document is over 7,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an annual report, audit report, or earnings release. The presence of detailed cash flow statements and notes aligns with the definition of an Interim / Quarterly Report (IR). H1 2008
2008-01-29 English
Completion of Share Purchase Plan 8 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a New Issue Announcement and Application for Quotation of Additional Securities submitted to the Australian Stock Exchange (ASX). It details the completion of a Share Purchase Plan (SPP), the allotment of new fully paid ordinary shares, underwriting details, and the application for quotation of these new shares. The document is regulatory in nature, announcing a capital raising event and the issuance of new shares, including detailed information about the securities issued, their terms, and the quotation agreement with ASX. It does not contain financial statements or comprehensive financial performance data, nor is it a report or presentation. It is a formal announcement related to capital structure changes and share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (11,375 characters) supports that it is a full announcement, not a brief notice or report publication announcement.
2007-12-20 English
BIT225 Phase I Trial Data Presented at International Meeting 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a short announcement (only 4110 characters) from Biotron Limited dated 13 December 2007. It reports that data from a Phase I clinical trial of their product BIT225 was presented at international scientific meetings. The document describes the content of the presentations and the significance of the data but does not contain any financial statements, detailed financial analysis, or regulatory filings. It is an update on clinical trial progress and presentations rather than a formal report or regulatory filing. The document is not a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or management report. It is also not a voting result, capital update, or legal proceeding. Given its short length and nature, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial data presentations and company progress, which does not fit other specific categories.
2007-12-12 English
Shareholder update 3 pages ?Kb
Report Publication Announcement Classification · 95% confidence The document is a short letter dated 23 November 2007 addressed to the Australian Stock Exchange Limited, referencing a shareholder update. It mentions an attachment of a document updating shareholders on the progress of the company's projects. The text is only 683 characters, indicating it is a brief announcement rather than a full report. There is no detailed financial data or comprehensive report content present. The letter serves as a notification or announcement about the shareholder update document rather than the report itself. According to the 'MENU VS MEAL' rule, this is an announcement of a report, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2007-11-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.